Abstract Number: 1753 • ACR Convergence 2021
Hydroxychloroquine Blood Levels Are Associated with Reduced SLE Disease Activity and Improvements in Cardiovascular Risk Factors
Background/Purpose: In SLE, treatment with hydroxychloroquine (HCQ) has been shown to be associated with reduced SLE flares and reduced risk of damage in several different…Abstract Number: 0206 • ACR Convergence 2021
Hydroxycloroquine-Induced Atrioventricular Block in Inmune-Mediated Diseases. Single University Center Study of 293 Patients
Background/Purpose: Hydroxychloroquine (HCQ) is an extensively used drug in immune-mediated diseases (IMID). Despite its general safety, HCQ can cause serious toxicity such as heart conduction…Abstract Number: 1762 • ACR Convergence 2021
Hydroxychloroquine Alone Does Not Increase QTc in the Absence of Other QT-prolonging Medications
Background/Purpose: Hydroxychloroquine (HCQ) is one of the widely used immunomodulator in rheumatology. Its temporary trendy use during the early phase of COVID pandemic stresses its…Abstract Number: 0306 • ACR Convergence 2021
Allergic Disorders in Primary Sjögren’s Syndrome Compared with Rheumatoid Arthritis
Background/Purpose: Allergic disorders are occasionally seen in patients with primary Sjögren's syndrome (pSS) [1]. Risk factors are unclear for allergic disorders.We aimed to compare the…Abstract Number: 0439 • ACR Convergence 2021
Predictors of Rheumatic Immune-related Adverse Events and de Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor-treatment for Cancer
Background/Purpose: Immune-related adverse events (irAEs) are a frequent and serious complication of immune checkpoint inhibitor (ICI) treatment for cancer, which can resemble primary rheumatic diseases.…Abstract Number: 0646 • ACR Convergence 2021
Dark Adaptometry Screening for Hydroxychloroquine Retinopathy: A Pilot Study
Background/Purpose: Hydroxychloroquine (HCQ) is widely used in the treatment of rheumatic diseases. The use of HCQ is complicated by HCQ-induced retinopathy, which may lead to…Abstract Number: 0712 • ACR Convergence 2021
Immune Checkpoint Inhibitor-related Myotoxicity : Musculoskeletal and/or Neuromuscular Junction Disorder ?
Background/Purpose: Immune checkpoint inhibitor (ICI)-related adverse events (irAE) recently emerged as new diseases in the field of auto-immunity. Among them, ICI-related myotoxicity has the highest…Abstract Number: 0753 • ACR Convergence 2021
Patient-Reported Burden of Adverse Drug Reactions Attributed to the Use of Adalimumab and Etanercept in Patients with Inflammatory Rheumatic Diseases
Background/Purpose: Health care professionals tend to focus on adverse drug reactions (ADRs) with the highest clinical impact. Subsequently, ADRs with less obvious clinical impact but…Abstract Number: 0989 • ACR Convergence 2021
Risk Factors for Hydroxychloroquine Retinopathy and Its Subtypes – Prospective Adjudication Analysis of 4,899 Incident Users
Background/Purpose: Hydroxychloroquine (HCQ) is a key treatment for patients with lupus and other rheumatic diseases; however, the known risk factors for HCQ retinopathy (its major…Abstract Number: 1038 • ACR Convergence 2021
Outcomes of Hydroxychloroquine Screening for Retinopathy in a Cohort of Patients with Rheumatological Conditions
Background/Purpose: Hydroxychloroquine (HCQ) is used to treat rheumatoid arthritis (RA), connective tissue disease (CTD) and other inflammatory conditions. In 2018, the United Kingdom Royal College…Abstract Number: 1160 • ACR Convergence 2021
Evaluation of HCQ Side Effects in New and Prevalent Users over a 20 Year Period Using a Large Database
Background/Purpose: Despite being used for more than 70 years as a conventional (cs) DMARD, very little is known about the overall side effect (SE) profile…Abstract Number: 1161 • ACR Convergence 2021
Patient Preferences for Hydroxychloroquine in Systemic Lupus (SLE)
Background/Purpose: Although hydroxychloroquine (HCQ) has been shown to reduce SLE flares, concerns exist regarding side effects from long-term use. Very little information is available on…Abstract Number: L08 • ACR Convergence 2020
Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators)
Background/Purpose: Febuxostat and allopurinol are uric acid lowering agents. Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency (EMA) recommended a post-authorization…Abstract Number: 0952 • ACR Convergence 2020
Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial
Background/Purpose: Pegloticase, a recombinant, pegylated uricase, is used for treatment of gout in patients who fail oral urate lowering therapy (ULT). Despite successful reduction of…Abstract Number: 1844 • ACR Convergence 2020
Hydroxychloroquine and QTc Prolongation in a Cohort of SLE Patients
Background/Purpose: Hydroxychloroquine (HCQ) is an antimalarial drug used in the treatment of systemic lupus erythematous (SLE). Cardiac toxicity is very rare in SLE, but has…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- 8
- Next Page »